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Abstract
The protein kinase C (PKC) family of serine–threonine kinases has been implicated in behavioral 
responses to opiates, but little is known about the individual PKC isozymes involved. Here, we 
show that mice lacking PKCε have increased sensitivity to the rewarding effects of morphine, 
revealed as the expression of place preference and intravenous self-administration at very low 
doses of morphine that do not evoke place preference or self-administration in wild-type mice. 
The PKCε null mice also show prolonged maintenance of morphine place preference in response 
to repeated testing when compared with wild-type mice. The supraspinal analgesic effects of 
morphine are enhanced in PKCε null mice, and the development of tolerance to the spinal 
analgesic effects of morphine is delayed. The density of μ-opioid receptors and their coupling to 
G-proteins are normal. These studies identify PKCε as a key regulator of opiate sensitivity in 
mice.
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Opiate drugs are important for the treatment of severe pain, but their usefulness is 
constrained by their significant abuse potential, with addiction to opiates being a major 
social and economic problem throughout the world. In the United States alone, the economic 
cost of heroin addiction is estimated at $22 billion a year (Mark et al. 2001), and the 
National Survey on Drug Use and Health (NSDUH) estimates that lifetime heroin users in 
the United States number 3.1 million (NSDUH 2004). An understanding of the molecular 
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mechanisms by which opiates produce their euphoric and analgesic effects is thus vital to 
aid the design of novel analgesics with reduced abuse potential.
Protein kinase C (PKC) is a family of intracellular, phospholipid-dependent, serine–
threonine kinases that transduce signals involving lipid second messengers (Nishizuka 2001; 
Olive & Messing 2004). The family is encoded by nine genes and is divided into three 
subclasses based on differences in structure and response to second messengers. 
Conventional PKCs (α, β, γ) are activated by calcium and diacylglycerol, novel PKCs (δ, ε, 
η, θ) are activated by diacylglycerol but not by calcium and atypical aPKCs (ζ and τ/λ) are 
insensitive to calcium and diacylglycerol but are modulated by other lipids. All isozymes 
except PKCθ are found in the brain, and PKCγ is found only in the central nervous system. 
Recent evidence indicates a role for the PKC family in behavioral responses to opiates. For 
example, the PKC inhibitor calphostin C prevents the development of morphine-induced 
place preference (Narita et al. 2001a), and chronic morphine treatment produces an increase 
in membrane-associated PKC activity in the limbic forebrain (Narita et al. 2002b).
Determining the role of individual PKC isozymes in mediating behavioral responses to 
morphine is difficult to achieve pharmacologically, as currently available inhibitors such as 
Ro 31-8220 and GF 109203x do not exhibit specificity for individual PKC isoforms 
(Wilkinson et al. 1993), and have even been shown to affect kinases other than PKC, such as 
glycogen synthase kinase-3 (Hers et al. 1999), mitogen-activated protein kinase-activated 
protein (MAPKAP) kinase 1β and p70 S6 kinase (Alessi 1997). Ro 31-8220 has even been 
shown to directly inhibit sodium channels (Lingameneni et al. 2000). Other PKC inhibitors 
such as calphostin C also have little specificity for individual PKC isoforms and affect 
targets other than PKC, including Ras guanyl nucleotide releasing protein (RasGRP) 
(Lorenzo et al. 2000), phospholipase D (Sciorra et al. 2001) and L-type calcium channels 
(Hartzell & Rinderknecht 1996). Thus, we chose a genetic approach by studying behavioral 
responses to morphine in mice lacking the epsilon isoform of PKC. A similar approach 
revealed that mice lacking PKCγ show reduced place preference for morphine (Narita et al. 
2001a) but enhanced morphine analgesia (Narita et al. 2001b).
There is evidence that PKCε is activated by opiates. Treatment of neurons cultured from 6-
day-old chicken embryos with the μ-opioid receptor agonist morphiceptin increases PKCε 
activity as measured by kinase and membrane translocation assays (Mangoura & Dawson 
1993). Also, treatment of the neuronal cell line SH-SY5Y with 1 μM D-Ala2, Nme-Phe4, 
G1yol5-enkephalin (DAMGO) for 4 h causes translocation of PKCε from cytosol to 
membrane fractions, whereas more prolonged treatment for 48 h causes an almost complete 
disappearance of PKCε immunoreactivity from these cells (Kramer & Simon 1999). 
DAMGO (1 μM)-stimulated PKCε translocation has also been observed after 1 h in SH-
SY5Y cells (Mandyam et al. 2003). These results suggest that PKCε is a downstream 
mediator of μ-opioid receptor stimulation, raising the possibility that PKCε modulates 
behavioral responses to opiates.
Here, we investigated whether PKCε null mice show altered responses to opiates using 
models of both addictive behavior and analgesia. We report that these mice are more 
sensitive to both the analgesic and the rewarding effects of morphine and acquire 
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intravenous morphine self-administration at a training dose that fails to induce self-
administration in wild-type mice. These results identify PKCε as an important modulator of 
behavioral responses to morphine.
Materials and methods
Mice
The PKCε null mice were generated by homologous recombination as described previously 
(Khasar et al. 1999) and back-crossed onto the C57BL/6J background for more than 10 
generations. To generate mice for experiments, we crossed C57BL/6J PKCε+/− mice with 
129/S4 mice to generate F1 hybrid PKCε+/− mice. These were intercrossed to generate F2 
hybrid littermates for experiments. Mice were genotyped by polymerase chain reaction of 
tail biopsies (5- to 10-mm fragment) obtained from non-anesthetized, 10-day-old pups. 
Experimentally naive PKCε null and wild-type mice were housed in standard Plexiglas 
cages with food and water available ad libitum. The colony room was maintained on a 12-h 
light:12-h dark cycle with lights on at 0600 h. Mice were between the ages of 2 and 6 
months at the time of testing. Animal care and handling procedures were in accordance with 
Ernest Gallo Clinic and Research Center Institutional Animal Care and Use Committee and 
National Institutes of Health guidelines.
Conditioned place preference
Mice were trained in Med Associates (Georgia, VT, USA) Place Preference Chambers. 
These consisted of two test chambers, 16.8 × 12.7 × 12.7 cm, separated by a central access 
chamber, 7.2 × 12.7 × 12.7 cm. One test chamber was white with a grid floor, the other 
black with a rod floor. The central access chamber was gray with a smooth floor. Mice were 
given a 30-min habituation session, consisting of free access to all chambers, on the day 
immediately prior to commencement of training. Mice were trained by being placed into the 
central access chamber immediately following morphine or saline administration. The door 
to the appropriate side was remotely opened and then closed once the mouse had entered the 
test chamber. The morphine-paired compartment was assigned randomly across subjects. 
Mice were trained in four 30-min sessions. Mice were treated with morphine every other 
day, with saline treatment on intervening days. On the day immediately following the final 
training session, mice were tested by allowing them free access to all chambers for 30 min. 
A mouse was considered to have developed conditioned place preference for morphine if the 
time it spent in the drug-paired chamber was significantly greater than the time spent in the 
non-drug-paired side as determined by a Wilcoxon signed rank test where P < 0.05 (Newton 
et al. 2004). The same analysis was performed on data obtained during the habituation 
session performed prior to the first training day to detect any baseline preference for a 
particular chamber. None was found in either genotype (data not shown) and thus an 
unbiased place preference protocol was used. Naive mice were used for every morphine 
dose. Extinction of conditioned place preference was measured by repeating only the test 
procedure on the days indicated.
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Mice were placed one at a time onto to a 52°C hotplate (Accusan Instruments, Columbus, 
OH, USA), and the time that elapsed until they licked or withdrew their paws, or jumped 
from the plate, was recorded by an examiner blind to their genotype. The mice were then 
given an injection of morphine [1–10 mg/kg intraperitoneal (i.p.) in saline] and retested 30 
min later. Mice were not permitted to exceed 30 seconds of exposure to the hotplate to 
prevent prolonged painful stimulation. Data were analyzed to account for this artificial 
ceiling and were calculated as the percentage of the maximum possible effect (%MPE) by 
the following formula: 100 × [(drug response time – basal response time)/(30 seconds – 
basal response time)] = %MPE (Balmberg & Bannon 1999). Data were analyzed by two-
way analysis of variance (ANOVA) with factors for dose and genotype, from 5 to 10 mice 
per morphine dose and 33 to 35 mice for baseline measurements.
Tail-flick assay
Mice were held in a towel and their tails lowered into a beaker of water held at 54°C. 
Latency to remove the tail from the hot water was recorded. Animals were then given an 
injection of morphine (1–10 mg/kg i.p.) and the latency was recorded again 30 min later. 
Mice were not permitted to exceed 30 seconds of exposure to hot water to prevent prolonged 
painful stimulation. Data were expressed as %MPE (see above), using 4–10 mice per 
morphine dose. Baseline values are reported from all 25 mice. To assess the development of 
tolerance to morphine analgesia, the same procedure was repeated daily, using 10 mg/kg 
morphine only, for 7 days, using 10 mice per genotype. For 2 days prior to all tail-flick 
experiments, mice were acclimatized to being held in the towel.
Intravenous self-administration surgery
Mice were placed under general anesthesia with an isoflurane vapor mixture and then 
surgically prepared with chronic silastic jugular catheter implants (Roberts et al. 1997). The 
catheters were made of silastic tubing (inner diameter 0.3 mm; outer diameter 0.64 mm; 7-
mm length). The jugular catheter was passed subcutaneously to a polyethylene assembly 
mounted on the back of the animal. This assembly consisted of a guide cannula (C313G; 
Plastics One, Roanoke, VA, USA), which was bent at a right angle halfway down the 
cannula. Silastic tubing was made soft with a short solvent bath (Hemo-De, 1 min) and 
slipped over the cannula. After drying, the cannula-tubing junction was encased in dental 
cement with a piece of fabric mesh secured to the bottom. The mesh served to anchor the 
assembly subcutaneously. After shaving the areas for incision, and application of 70% 
alcohol and povidone/iodine solution, incisions were made in the mid-scapular region as 
well as anteromedial to the right forearm above the external right jugular vein. A catheter 
was passed subcutaneously from the dorsal incision to the ventral incision, and the silastic 
tubing was inserted into the jugular vein, and then tied gently with suture thread to the vein. 
The dorsal incision was closed, 30 μl of physiological saline was flushed through the 
catheter and the exit point was then capped with a Tygon stopper. Catheter patency was 
verified by administering 0.02 ml of sodium brevital (5 mg/ml; Monarch Pharmaceuticals, 
Bristol, TN, USA) on the day after surgery and after the self-administration sessions.
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Self-administration training and testing
Experimental sessions were conducted in mouse conditioning chambers (ENV-307W, Med 
Associates, St Albans, VT, USA) located within ventilated sound attenuation chambers. 
Each chamber was equipped with two levers on one wall spaced 5.5 cm apart. A fixed ratio 
1 (FR 1) schedule of reinforcement was used whereby responses on the active lever resulted 
in the activation of the infusion pump for 5 seconds to deliver 25 μl of solution from a 10-ml 
syringe. Immediately following morphine delivery, there was a 20-second time-out period to 
prevent overdose. A cue light immediately above the active lever came on at the time of 
infusion and remained on throughout the time-out period. Responses on the inactive lever 
and during the time-out period were recorded but had no programed consequences. Sessions 
lasted for 60 min. Intravenous drug infusions were delivered by a software-operated infusion 
pump (Med Associates, St Albans, VT, USA) placed outside the sound-attenuating box, 
through a liquid swivel and a syringe. Tygon microbore tubing connected the components of 
the infusion apparatus to each other and to the exit port of the catheter.
[3H]DAMGO autoradiography
Naive mice were euthanized with CO2 followed by decapitation, and their brains were 
rapidly removed and placed in isopentane at −50°C for 15 seconds. Brains were then stored 
at −80°C. Cryosections were thaw-mounted onto gelatin slides, dessicated and stored at 
−80°C. For autoradiography, slides containing precut sections were preincubated in 50 mM 
Tris–HCl, pH 7.4, at 25°C for 30 min, followed by incubation in 5 nM [3H]DAMGO 
(American Radiolabeled Chemicals Inc., St Louis, MO, USA) 50 Ci/mmol) in 50 mM Tris–
HCl for 60 min at 27°C. Non-specific binding was assessed using adjacent sections 
incubated in the presence of 1 μM naloxone (Surratt et al. 1994). Slides were rinsed twice, 5 
min each in ice-cold 50 mM Tris–HCl, pH 7.4, and then dipped in ice-cold distilled water. 
They were then dried overnight at 4°C and placed in an X-ray cassette with Tritium 
Microscales (Amersham-Pharmacia, Piscataway, NJ, USA) and exposed to Kodak MR film 
with an intensifying screen for 3–5 weeks at −80°C. Autoradiograms were scanned using a 
flat-bed scanner and analyzed using the program IMAGE j (http://rsb.info.nih.gov/ij). The 
amount of bound [3H]DAMGO was calculated from optical density values using the tritium 
standards. Genotypes were then compared by two-tailed, unpaired t-tests for each brain 
region.
GTP-γS binding
The coupling of μ-opioid receptors to G-protein activation was assessed by measuring the 
binding of radiolabeled GTY-γS to brain slices following incubation with the μ-receptor 
agonist DAMGO. Precut brain frozen sections were preincubated in TME buffer (100 mM 
NaCl, 3 mM MgCl2, 0.2 mM EGTA, 50 mM Tris–HCl, pH 7.4, and 1 U/ml adenosine 
deaminase) for 10 min at 25°C. Sections were then incubated in TME with 2 mM guanosine 
diphosphate (GDP) at 25°C for 15 min. Sections were subsequently incubated with TME 
containing 20 μM DAMGO, 2 mM GDP, 0.04 nM [35S]GTP-γS (Amersham-Pharmacia, 
>1000 Ci/mmol) and 0.2 mM dithiothreitol for 2 h at 25°C. Non-specific binding was 
assessed using adjacent sections incubated in the presence of 10 μM GTP-γS (Sigma, St 
Louis, MO, USA). Sections were washed twice in 50 mM Tris–HCl for 2 min at 5°C, then 
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once in deionized water for 1 min at 5°C. Slides were dried overnight at 4°C under a fan and 
apposed to Kodak MR film for 72 h. Autoradiograms were scanned using a flat-bed scanner 
and analyzed using the program IMAGE j (http://rsb.info.nih.gov/ij). The percent 
stimulation was calculated by comparing [35S]GTP-γS binding in DAMGO-stimulated and 
unstimulated sections. Genotypes were then compared by two-tailed, unpaired t-tests for 
each brain region.
Results
PKCε null mice show increased sensitivity to morphine-induced conditioned place 
preference
The PKCε null and wild-type mice were trained in a conditioned place preference paradigm 
with a range of morphine doses. Both genotypes showed significant place preference when 
trained with either 5 mg/kg or 0.5 mg/kg morphine, but only PKCε null mice showed 
conditioned place preference at the very low training dose of 0.1 mg/kg morphine (Fig. 1a). 
We also tested the maintenance of place preference for morphine in mice trained with 5 
mg/kg morphine. In wild-type animals, place preference was reduced 17 days after the 
original trial and was absent at 30 days after the original test. In contrast, PKCε null mice 
showed robust maintenance of place preference during the 30-day period (Fig. 1b). These 
results demonstrate that PKCε null mice are more sensitive to the rewarding properties of 
morphine and that they retain memory of morphine reward longer than wild-type littermates.
Operant morphine self-administration
Since PKCε null mice were more sensitive to the rewarding effects of morphine in the 
conditioned place preference paradigm, we wished to determine if they could acquire 
morphine self-administration at a low training dose (0.1 mg/kg). We trained mice to self-
administer morphine intravenously over seven daily 60-min sessions on an FR 1 schedule. 
The PKCε null mice demonstrated a significant level of responding on the active lever 
compared with the inactive lever, whereas wild-type mice did not (Fig. 2a). A two-way 
ANOVA with factors for lever and genotype did not reveal an overall main effect of 
genotype (F(1,34) = 2.23, P = 0.1449) or lever (F(1,34) = 1.57, P = 0.2187) but did reveal a 
significant interaction between the two factors (F(1,34) = 4.319, P = 0.0453). Post hoc 
Bonferroni tests revealed a significant difference between levers for PKCε null mice only (P 
< 0.05). The administration dose was then reduced to 0.05 mg/kg, and the null mice reduced 
their responding such that there was no longer a significant difference between the active 
and inactive levers in either genotype by two-way ANOVA (Fig. 2b). In addition, PKCε null 
mice earned a greater number of infusions than wild-type mice during the 0.1-mg/kg 
morphine sessions (Fig. 2c); a two-way repeated measures ANOVA with a between-subjects 
factor for genotype and a repeated measure for trial showed an effect of genotype (F(1,204) = 
8.751, P = 0.0088) and post hoc Bonferroni tests revealed a significant difference in trials 3 
and 4 (P < 0.05). These data indicate that, at a low-infusion dose, PKCε null mice 
demonstrate morphine self-administration whereas wild-type mice do not. The overall 
response rates were quite low even for the PKCε null mice, possibly due to these animals 
being C57BL/6 × 129/S4 hybrids, since the 129 background has been associated with low 
levels of operant self-administration (Kuzmin & Johansson 2000).
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PKCε null mice show delayed development of analgesic tolerance by tail-flick and 
enhanced morphine analgesia on the hotplate
Having established that PKCε null mice show enhanced sensitivity to morphine conditioned 
place preference, we wished to investigate whether sensitivity was altered for morphine-
induced analgesia. We used two separate measures of analgesia, the tail flick, which 
measures predominantly spinal responses, and the hotplate, which measures predominantly 
supraspinal responses (Javed et al. 2004; South & Smith 1998; Vylicky 1984). In the tail-
flick assay, there was no genotypic difference in baseline responding (Fig. 3a) or in 
morphine dose response (Fig. 3b). However, when assessing the development of tolerance to 
morphine analgesia in the tail-flick assay using daily repeated testing after 10 mg/kg 
morphine, PKCε null mice showed delayed development of tolerance (Fig. 3c). A two-way 
repeated measures ANOVA with a between-subjects factor for genotype and a repeated 
measure for time showed an effect of genotype (F(1,95) = 5.53, P = 0.032) and day (F(6,95) = 
43.06, P < 0.001) with an interaction between these factors (F(6,95) = 2.719, P = 0.018). Post 
hoc Bonferroni tests showed a significant difference (P < 0.001) in %MPE between wild-
type and PKCε null mice on day 3. Baseline latency increased during repeated testing, but 
this did not differ between genotypes (Fig. 3a), and a two-way repeated measures ANOVA 
with factors for genotype and trial showed a significant effect of trial (F(6,96) = 14.84, P < 
0.0001) but no effect of genotype (F(1,96) = 0.17, P = 0.6889) and no interaction between 
genotype and trial (F(6,96) = 1.08, P = 0.3794).
To determine sensitivity to morphine in an assay of supra-spinal nociception, we performed 
a hotplate assay. Again, there was no difference in baseline response (Fig. 3d), but the 
analgesic response to morphine was greater in PKCε null mice (Fig. 3e). A two-way 
ANOVA showed significant main effects of genotype (F(1,60) = 6.78, P = 0.012) and dose 
(F(3,60) = 22.23, P < 0.001) with a difference between the genotypes at 10 mg/kg 
demonstrated by post hoc Tukey tests. Tolerance to morphine was not measured on the 
hotplate as repeated testing causes a reduction in response latency times even in drug-free 
animals, and genotypic differences in this habituation may affect the results (Gebhart et al. 
1971; Plone et al. 1996).
PKCε null mice show normal μ-opioid receptor density and activation
Since PKCε null mice showed enhanced sensitivity to the rewarding and analgesic 
properties of morphine, we considered whether this was associated with increased μ-opioid 
receptor density or enhanced receptor activation of G-proteins. Receptor density was 
assessed using [3H]DAMGO autoradiography and receptor activation of G-protein signaling 
by [35S]GTP-γS binding after DAMGO stimulation. We found no differences between 
PKCε null and wild-type mice in either receptor density or G-protein activation in 
hippocampus, striatum or thalamus (Fig. 4a,b).
Discussion
Our results demonstrate a clear role for PKCε in regulating morphine reward and analgesia. 
PKCε null mice develop conditioned place preference to a very low training dose of 
morphine (0.01 mg/kg) that does not cause place preference in wild-type mice and maintain 
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a robust morphine place preference over a 30-day drug-free period during which time place 
preference is extinguished in wild-type mice. Morphine analgesia is enhanced in PKCε null 
mice and intravenous morphine self-administration behavior is demonstrated at a low 
training dose that does not induce self-administration in wild-type mice. The differences in 
place conditioning between wild-type and PKCε null mice are not due to altered ability to 
learn the task, as both genotypes displayed conditioned place preference of similar 
magnitude when administered 5 mg/kg morphine. Therefore, our findings indicate that 
PKCε is an important regulator of morphine’s behavioral effects in animals and that 
pharmacological inhibition of PKCε may enhance responses to opioid drugs.
We observe enhanced responses to morphine in multiple behavioral measures of both 
reward and analgesia. Although addiction and analgesic tolerance both require chronic 
opiate exposure, it is generally believed that they are distinct biological phenomena (Hunt & 
Urch 2006). There are multiple possible substrates for PKCε that may modulate behavioral 
responses to opiates. Although PKC has been shown to directly phosphorylate the μ-opioid 
receptor (Zhang et al. 1996), our biochemical data, showing that μ-opioid receptor density 
and G-protein coupling are unchanged in PKCε null mice, suggest that PKCε acts 
downstream of the μ-opioid receptor in normal mice. Two of the principal downstream 
effectors of the μ-opioid receptor, via the release of G-protein βγ subunits, are G-protein-
coupled inward rectifier K+ channels (GIRKs) (Bailey et al. 2004; Ikeda et al. 2002) and N-
type calcium channels (Rusin & Moises 1995; Wu et al. 2004). Protein kinase C has been 
shown to phosphorylate and potentiate the function of GIRKs (Mao et al. 2004). There is 
also evidence that PKCε could modulate opiate responses via N-type calcium channels; βγ-
mediated inhibition of N-type calcium channel function is antagonized by PKC activation 
(Cooper et al. 2000). It is likely that PKCε is the PKC that performs this function since 
PKCε forms a complex with the N-type calcium channel pore-forming α subunit through the 
enigma homolog 1 protein; moreover, a peptide inhibitor of PKCε inhibits both this 
interaction and phorbol ester enhancement of N-type channel function (Maeno-Hikichi et al. 
2003). Studies showing stimulation of PKCε by μ-opioid-specific ligands (Kramer & Simon 
1999; Mandyam et al. 2003) imply the existence of a negative feedback mechanism to 
counter μ-opioid inhibition of N-type calcium channels. These studies predict that, in mice 
lacking PKCε, this inhibitory feedback mechanism would be lost, allowing activation of μ-
opioid receptors to result in more profound behavioral effects. Future studies utilizing 
pharmacological agents or double knockout mice may help determine whether PKCε 
modulates responses to opiates through actions at these candidate substrates.
The delayed extinction of morphine conditioned place preference is interesting as it 
represents an animal model of some of the behaviors displayed by human addicts who fail to 
inhibit their behavioral response to cues or contexts that are no longer rewarding. This 
deficit is thought to arise in part from impaired prefrontal cortex function (Jentsch & Taylor 
1999; Kalivas & Volkow 2005). We are extending our studies to determine whether the 
extinction deficit shown here by PKCε null mice trained to express a conditioned place 
preference for morphine generalizes to a failure to extinguish Pavlovian conditioning or is 
specific for certain drugs.
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Interestingly, our data indicate that acute responses to morphine in PKCε null mice are 
enhanced only in supraspinal systems, as the morphine dose–response curve and response 
magnitude were unaltered in a tail-flick assay, which examines spinal analgesia (South & 
Smith 1998; Vylicky 1984). However, we observed that the development of tolerance to the 
analgesic effects of morphine was delayed in the tail-flick assay. The molecular mechanisms 
by which repeated morphine exposure produces behavioral tolerance remain highly 
controversial (Bailey & Connor 2005), but numerous lines of evidence implicate a role for 
PKC. Behavioral studies demonstrate that co-administration of PKC inhibitors retards the 
development of spinal analgesic tolerance to morphine (Granados-Soto et al. 2000; Narita et 
al. 1994), and biochemical studies show that chronic morphine increases PKC activity in the 
spinal cord (Li & Roerig 1999). Our data suggest that PKCε may be an important isoform 
involved in these effects.
Although we have not assayed the pharmacokinetics of morphine in PKCε null mice, we do 
not see a difference in acute analgesic sensitivity in the tail-flick assay, suggesting that there 
is no baseline difference in morphine distribution or clearance. Since we did not measure 
morphine pharmacokinetics following repeated morphine administration, it is possible that 
the delayed development of analgesic tolerance we observed in PKCε null mice might be 
due to differences in pharmacokinetics during repeated morphine exposure. However, we 
think this is unlikely since it is generally believed that analgesic tolerance is not caused by a 
change in morphine pharmacokinetics following chronic drug administration, and this is 
supported by studies in rats (Mas et al. 2000).
The strategy of using knockout mice to determine the role of specific molecules in behavior 
has some limitations, such as the carry over of genes from the genetic background used to 
generate the embryonic stem (ES) cells (Wolfer et al. 2002). In the present study, the ES 
cells used to generate the null mutant were from the 129/S4 background (formerly 129/
SvJae; see http://jaxmice.jax.org/info/bulletin/bulletin01.html). F1 hybrid mice were 
subsequently crossed into the C57BL/6 background (Khasar et al. 1999). Thus, the 
morphine phenotype of the PKCε null mice may be contributed to by genes from the 129/S4 
background. However, it has been demonstrated that both 129/P3 and 129/SvJ mice have the 
opposite phenotype to PKCε null mice, with reduced sensitivity to morphine in measures of 
analgesia (129/P3) (Kest et al. 2002) and the development of morphine conditioned place 
preference (129/SvJ) (Dockstader & van der Kooy 2001). Although the mice used in the 
cited studies are not exactly the same as the 129 strain used here, the results suggest that the 
morphine phenotype of the PKCε null mice is not due to flanking genes carried over from 
the 129/S4 background. Additional considerations when using knockout mice that carry the 
null mutation from birth are that the phenotypes observed may result from indirect effects of 
gene deletion in other organs besides the brain, from developmental changes or from 
changes in the abundance of other gene products that compensate for the missing gene 
(Crawley 2000; Stephens et al. 2002). Site-specific injections of adult wild-type animals 
with a lentivirus encoding short hairpin RNA directed against PKCε may help address some 
of these issues in the future.
The increased response of PKCε null mice to morphine in the place-conditioning assay 
stands in contrast to the response of PKCγ null mice, which show no place preference for 
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morphine (Narita et al. 2001b). This pattern resembles modulation of behavioral responses 
to ethanol by these PKC isozymes, where opposing roles for PKCε and PKCγ have been 
documented, with PKCε null mice being more sensitive to ethanol intoxication and 
voluntarily consuming less ethanol (Hodge et al. 1999), and PKCγ null mice showing the 
opposite phenotype (Harris et al. 1995). These behavioral phenotypes appear to correlate 
with opposing roles for these PKC isozymes in regulating the sensitivity of gamma-
aminobutyric acid (GABAA) receptors to allosteric modulation by ethanol (Harris et al. 
1995; Hodge et al. 1999; Proctor et al. 2003). Whether opposing actions at targets such as 
GABAA receptors mediate opposite effects of PKCε and PKCγ on behavioral responses to 
opiates remains to be investigated.
In contrast to their opposite responses in place-conditioning assays, both PKCε and PKCγ 
null mice show an enhanced analgesic response to morphine (Narita et al. 2001b) and 
delayed development of analgesic tolerance (Zeitz et al. 2001). For PKCγ null mice, unlike 
PKCε null mice, this may result from increased G-protein activation after μ-opioid receptor 
stimulation (Narita et al. 2002a). Protein kinase Cε is expressed throughout the central and 
peripheral nervous system (Choi et al. 2002) and is a key mediator of signal transduction 
within primary afferent nociceptors that promotes inflammatory hyperalgesia (Aley et al. 
2000; Khasar et al. 1999). In contrast, PKCγ is not expressed in the peripheral nervous 
system, and appears instead to modulate nociception through actions in the dorsal horn of 
the spinal cord, where it is involved in reorganization of spinal cord circuitry following 
nerve injury (Martin et al. 1999, 2001). Given the different anatomical distribution of these 
two PKC isozymes and the distinct morphine phenotypes of mutant mice lacking them, it is 
likely that PKCε and PKCγ act through different mechanisms to enhance sensitivity to 
opiate analgesia. These studies demonstrate the importance of using isozyme-specific 
reagents to detect PKC isozyme-specific functions as commonly available pharmacological 
PKC inhibitors show little or no specificity for different PKC isozymes.
In summary, our data demonstrate that in mice lacking PKCε, the acute rewarding and 
central analgesic effects of morphine are enhanced, whereas acute spinal analgesic responses 
are unchanged. However, the development of tolerance to spinal analgesia is delayed, 
suggesting that PKCε operates through multiple mechanisms to regulate behavioral 
responses to morphine. Determining these mechanisms may aid in the development of novel 
analgesics with reduced abuse potential.
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Figure 1. Morphine conditioned place preference is enhanced in PKCε null mice
(a) PKCε null mice developed conditioned place preference to a sub-threshold dose of 
morphine (0.1 mg/kg i.p.) that did not cause place preference in wild-type mice. Both 
genotypes developed preference to 0.5 and 5 mg/kg morphine. (b) Place preference to 5 mg 
morphine is maintained for a 30-day period in PKCε null mice but extinguishes in wild-type 
mice. Results are mean ± standard error of the mean values from 10 to 11 mice of each 
genotype. * P < 0.05 compared with the saline-paired side by Wilcoxon signed rank test.
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Figure 2. Morphine self-administration is enhanced in PKCε null mice
Mice were implanted with intravenous catheters delivering morphine on an FR 1 schedule 
for thirteen 60-min sessions (0.1 mg/kg per infusion for seven sessions, 0.05 mg/kg for six 
sessions). PKCε null mice showed significantly more responding on the active vs. the 
inactive lever for 0.1 mg/kg infusions, whereas wild-type mice did not show preferential 
responding on either lever (a). This preference for the active lever was abolished when the 
infusion dose was reduced to 0.05 mg/kg (b). In addition, the total number of rewards earned 
by PKCε null mice was greater than that earned by wild-type mice (c). *P < 0.05 compared 
with wild-type mice at that dose by post hoc Bonferroni tests.
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Figure 3. Acute supraspinal opioid analgesia is enhanced in PKCε null mice, whereas acute 
spinal analgesia is normal but the development of chronic tolerance is delayed
Morphine (1–10 mg/kg i.p.) effects on spinal nociception were quantified 30 min after 
injection by measuring the tail-flick latency using a 56°C water bath. (a) There was no 
genotypic difference in baseline latency (trial 1) or in the latencies measured before each 
injection of 10 mg/kg morphine during the tolerance experiment (trials 2–7) increased 
similarly over time in both genotypes. (b) There was also no genotypic difference in 
morphine dose response in naive non-tolerant mice. (c) The development of analgesic 
tolerance was assessed by repeated daily testing 30 min after a 10-mg/kg dose of morphine. 
PKCε null mice showed delayed development of tolerance compared with wild-type mice. 
*P < 0.05 compared with wild-type mice on day 3 by post hoc Bonferroni tests. Morphine 
effects on supraspinal nociception were quantified by measuring paw withdrawal latency in 
mice 30 min after morphine (1–10 mg/kg i.p.) injection using a hotplate set at 52°C. (d) 
There was no difference in baseline latency. (e) PKCε null mice showed significantly greater 
withdrawal latency after morphine. *P < 0.05 compared with wild-type mice at 10 mg/kg 
morphine by post hoc Bonferroni tests.
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Figure 4. μ-Opioid receptor density and activation are unchanged in PKCε null mice
(a) μ-Opioid receptor density measured by [3H]DAMGO autoradiography was unchanged in 
PKCε null mice when compared with wild-type mice (P > 0.05, two-tailed t-test). (b) μ-
Opioid receptor activation, measured by [35S]GTP-γS autoradiography after DAMGO 
stimulation, was unchanged in PKCε null mice compared with wild-type mice (P > 0.05, 
two-tailed t-test).
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